Trial Profile

Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ATL 101 Telix Pharmaceuticals (Primary) ; Lutetium-177 zadavotide guraxetan (Primary)
Indications Adenocarcinoma; Bone metastases; Liver metastases; Prostate cancer
Focus Adverse reactions; Therapeutic Use

Most Recent Events

11 Jun 2026 Planned number of patients changed from 48 to 42.
11 Jun 2026 Status changed from active, no longer recruiting to recruiting.
31 Mar 2026 Protocol has been amended to include one new arm (Experimental: Combination of 225Ac-J591 and 177Lu-PSMA-617) , it has changed from 1 to 2.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com